Review

Autophagy Modulation in Aggresome Formation: Emerging Implications and Treatments of Alzheimer’s Disease

Md. Ataur Rahman 1,2,3,*, MD. Hasanur Rahman 1, A. N. M. Mamun-Or-Rashid 4, Hongik Hwang 5, Sooyoung Chung 5, Bonglee Kim 1,2,*, and Hyewhon Rhim 5,6,*

1 Department of Pathology, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea; hasan079@bsmrstu.edu.bd
2 Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, 1-5, Hoegidong, Dongdaemun-gu, Seoul 02447, Korea
3 Global Biotechnology & Biomedical Research Network (GBBRN), Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, Kushtia 7003, Bangladesh
4 Anti-Aging Medical Research Center and Glycation Stress Research Center, Graduate School of Life and Medical Sciences, Doshisha University, Kyoto 602-8566, Japan; mamunbtgeiu@gmail.com
5 Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology (KIST), 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Korea; hongik.kist@gmail.com (H.H.); sooyoung@kist.re.kr (S.C.)
6 Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology (UST), Seoul 02792, Korea
* Correspondence: ataur1981rahman@hotmail.com (M.A.R.); bongleekim@khu.ac.kr (B.K.); hrhim@kist.re.kr (H.R.)

Abstract: Alzheimer’s disease (AD) is one of the most prevailing neurodegenerative diseases in the world, which is characterized by memory dysfunction and the formation of tau and amyloid β (Aβ) aggregates in multiple brain regions, including the hippocampus and cortex. The formation of senile plaques involving tau hyperphosphorylation, fibrillar Aβ, and neurofibrillary tangles (NFTs) is used as a pathological marker of AD and eventually produces aggregation or misfolded protein. Importantly, it has been found that the failure to degrade these aggregate-prone proteins leads to pathological consequences, such as synaptic impairment, cytotoxicity, neuronal atrophy, and memory deficits associated with AD. Recently, increasing evidence has suggested that the autophagy pathway plays a role as a central cellular protection system to prevent the toxicity induced by aggregation or misfolded proteins. Moreover, it has also been revealed that AD-related protein aggresomes could be selectively degraded by autophagosome and lysosomal fusion through the autophagy pathway, which is known as aggrephagy. Therefore, the regulation of autophagy serve as a useful approach to modulate the formation of aggresomes associated with AD. This review focuses on the recent improvements in the application of natural compounds and small molecules as a potential therapeutic approach for AD prevention and treatment via aggrephagy.

Keywords: Alzheimer’s disease (AD); aggregation; autophagy; aggresome; autophagosomes; aggrephagy

1. Introduction

Aggresomes are inclusion bodies that consist of aggregated cytoplasmic proteins induced by the overexpression or inhibition of certain proteins of the proteasome system [1], and the accumulation of incorrectly folded proteins is thought to contribute to the etiology of various neurodegenerative diseases [2]. Misfolded protein molecules processing has an important role in maintaining normal cellular function as well as homeostasis. Three protein quality systems have been found to degrade misfolded or aggregated protein, which are ubiquitinated proteasomal degradation, chaperone-mediated degradation, and selective autophagy or aggrephagy [3]. Previous studies have demonstrated that an increasing
number of AD-related proteins are associated with aggresomes [4], and non-pathological proteins could form invasive inclusion bodies as well. It is well-known that Aβ production in addition to oligomer accumulation is the key factor of AD pathogenesis [5]. Additionally, neurofibrillary tangles (NFTs) are caused by the neuronal microtubule-stabilizing hyperphosphorylation of tau protein [6]. Particularly, it is mentioned that the impaired degradation of these aggregated proteins molecules causes neuronal atrophy, cytotoxicity, synaptic impairment, memory deficits, and ultimately causes AD pathogenesis [7,8]. It has been hypothesized that autophagy manipulations might be a potentially promising therapeutic strategy target to modulate protein-aggregation-related diseases and toxicity. Recently, it has been revealed that AD-related protein aggregates might be recognized via several receptors which may be degraded through the autophagy–lysosome pathway (ALP); this process is known as the aggrephagy mechanism [4]. However, it has not been determined whether autophagy easily eliminates invasion caused by other proteins associated with AD. In this review, we would like to emphasize the susceptibility of AD-associated proteins to autophagy.

Autophagy, a cellular self-degradation system, can be exploited for the clearance and removal of misfolded protein, cellular constituents, processing antigens, tackling infectious organisms, sequestering additional organelles, suppressing tumors, and controlling cell growth [9,10]. Autophagy supports the clearance of aggregated or misfolded proteins during stress conditions, especially when ubiquitin–proteasome systems and chaperones become overwhelmed [11]. In general, autophagy is thought to be involved in several human diseases, for instance, heart and liver diseases, myopathies, cancer, and neurodegenerative disorders [12]; however, autophagy malfunction is additionally involved in several protein aggregation diseases [13]. Accumulating evidence has indicated that misfolded proteins can impair cell function and viability via a diversity of mechanisms such as proteasome inhibition, pore formation, as well as intracellular transport disruption [14,15]. It has been shown that misfolded protein production exceeds the capability of the ubiquitin–proteasome pathway and molecular chaperone system [16]. However, aggregated or misfolded protein is vigorously sequestered in a microscopically observable way, which forms pericentriolar structures, so-called aggresomes. These aggresomes are consequently degraded through autophagy, which is generally called the aggresome–autophagy pathway [16,17]. In this study, we reviewed the role of autophagy to modulate aggresomes and their potential therapeutic action for the treatment of AD, focusing on several small molecules which may potentially help improve AD treatment.

2. Molecular Mechanism of Alzheimer’s Disease

Alzheimer’s disease (AD) is one of the most prevailing neurodegenerative diseases, characterized by memory dysfunction and the presence of hyperphosphorylated tau and amyloid β (Aβ) aggregates in multiple brain regions, including the hippocampus and cortex [18]. The clinical and pathological appearance of AD comprises memory impairment and slowness while performing normal regular activities [19]. The main pathological features represent intracellular aggregates composed of the extracellular deposition of amyloid-β (Aβ) and phosphorylated tau protein that form neurofibrillary tangles (NFTs) leading to the formation of senile plaques [20–23] (Figure 1). Aggregated forms of tau protein are reported to appear in the proximal axon. Large, insoluble tau aggregates, which contain irreversibly phosphorylated tau species, do not move in the axons [13]. The production of toxic tau species may damage the transport system in the axon, reduce APP transport towards the synapse, cause APP accumulation in the soma, and thus lead to Aβ aggregation. Neurofibrillary tangles are formed via the hyperphosphorylation of a microtubule-associated protein known as tau, causing it to aggregate, or group, in an insoluble form. The precise mechanism of tangle formation is not completely understood, and it is still controversial as to whether tangles are a primary causative factor in disease or play a more peripheral role. It has been shown that the degree of cognitive impairment in diseases such as AD is significantly correlated with the presence of neurofibrillary tangles.
Investigating possible links between tau and NFTs is important for us to better understand processes that lead to the onset of AD at a mechanistic level. Increased Aβ load and NFTs in autophagic vacuoles further exacerbates autophagy stress and AD pathology, which eventually disturbs communication between neurons and their normal function, as well as finally resulting in neuronal death [24]. Synaptic autophagy vacuoles and aggregate clearance failure induce synaptic toxicity which results in diminished synaptic plasticity as a cause of memory dysfunction in AD.

Figure 1. Molecular mechanism of AD pathogenesis. Amyloid precursor protein cleaves by β-secretase and α-secretase, leading to the accumulation of neurotoxic Aβ plaque. Neurofibrillary tangles (NFTs) are aggregates of hyperphosphorylated tau protein. Aβ plaque and NFTs cause synaptic dysfunction and memory impairment, which are characteristics of AD.

3. Molecular Pathway of Autophagy Process

Autophagy can still be triggered to remove the unwanted components of cytoplasm such as protein clusters instead of injured mitochondria [25,26]; however, at times of strain and injury, autophagy mainly remains inside the cell homeostasis [27]. Unc-51-like kinase 1 (ULK1), as well as its start protein complex, is controlled mostly by metabolic sensor systems: mammalian target of rapamycin complex 1 (mTORC1) as a negative controller, and AMP-activated kinase (AMPK), a positive controller of autophagy [28]. The phosphatidylinositol 3-kinase 3-kinase (PI3K) type III nucleation intricate, whose best-known protein is Beclin-1, can then be activated to stimulate the nucleation of a pre-phagosome with the aid of ATG-9-bound vacuoles [29]. The lipidation of LC3-II (ATG-8) protein has a binding site that attaches to LC3-interacting motifs (LIRs) on autophagosome carriers which is responsible for the pre-phagosome [30]. With the help of ATG-4B, ATG-3, and ATG-7, this bonding with phosphatidylethanolamine is carried out with the assistance of an ATG-12-conjugation intricate as well as the phosphatidylinositol 3,4,5-triphosphate (PIP3) binding intricate [31]. Initially, LC3 is SPLIT by ATG-4B to disclose glycine remains formatting LC3-I which is shifted to ATG-7 (E1-similar enzyme which is shared with ATG-12) and is shifted to its particularly E2-like enzyme, ATG-3, and attached to the main group of phosphatidylethanolamines (PE), which generate LC3-II [32,33]. ATG-7 activates ATG-12 and makes the following intermediates with ATG-7 and ATG-10 (E2-similar enzyme) until it is conjugated with ATG-5 [34]: ATG-12/ATG-5 intricates work as E3-similar enzymes to encourage ATG-8-PE entanglement [35]. ATG-16L is needed for the natural process, but it does confirm that the lipidation happens in the correct cell wall. These actions cause the phagophore to enlarge and simply close, which controls the formation of the autophagosome [36]. Just before closing, the autophagosome’s dual layer merges to the
lysosomes, allowing the deterioration of the inward membrane and intra-autophagosome cargo to begin [37]. A detailed molecular mechanism of autophagy is presented in Figure 2.

4. Mechanism of Aggresome Formation

Aggrephagy is a selective form of autophagy that eliminates aggregated and ubiquitinated proteins [38]. The first stage of aggresome formation involves the accumulation of irregularly folded or unfolded proteins, packed into larger, insoluble aggregates and trans-
When ubiquitin proteasomal system is altered or overhauled, misfolded polyubiquitin proteins with themselves or join with existing aggresomes located at the MTOC, residing near the cellular centrosome. These aggregates are labeled with ubiquitin alone with heat shock proteins (Hsps), such as Hsp70, and their development in neurodegenerative diseases is demonstrated in Figure 1 [3,44–46]. Additionally, aggresomes are primarily surrounded by the cytoskeleton of intermediate filament, and a cage-like structure appears in the cytoskeleton, such as vimentin and keratin, along with neurofilaments [41,47] (Figure 3). This cage-like structure is known to promote structural stability and inhibit non-specific interactions. These aggresomes exert cellular cytotoxicity, but at a later stage, matured bilayer autophagosomes lose their activity [48]. The components of the ubiquitin–proteasome systems are concentrated or grouped into these assemblies before aggregate molecules are discarded through degradation or refolding [49]. Recently, it has been reported that the modulation of aggresome formation and assembly may serve as a novel approach to treat diseases associated with defects in protein conformation.

![Molecular mechanism of aggresome development and formation. Under normal conditions, misfolded and polyubiquitinated proteins are fragmented via the ubiquitin proteasomal system. When ubiquitin proteasomal system is altered or overhauled, misfolded polyubiquitin proteins accumulate and form to aggregate. In this case, ataxin-3-dexiquitinase interrelates and aggregates with polyubiquitinated proteins to form ubiquitin chain structure. In addition, HDAC6 binds these non-anchored C-terminal tails of ubiquitin to form aggregates and recruits them into the dynein motor complex.](image-url)
Histone deacetylase-6 enzyme (HDAC6), important for aggresome formation, is essential for microtubule transport machinery, and misfolded proteins produced from dendrites and axons are shifted towards the move to lysosome-rich MTOC [50]. HDAC6 is considered as the crucial controller of aggresome creation and maintains the central component of autophagy initiation [4]. In aggrephagy, MTOC is packed in aggresomes and degrades via lysosomes [51].

5. Clearance of Aggresomes through Autophagy

When the proteasomal degradation system is overwhelmed, the autophagy pathway is activated as an essential cellular defense system to resist incorrect folding and to prevent the accumulation of aggregated proteins [2,52]. In this system, poorly folded and aggregated proteins are selectively identified and transferred to the MTOC (center of microtubule tissue) around the central body via microtubule-based retrograde transport [53]. Accumulating evidence suggests that autophagy not only protects aggressive cells by chelating poorly folded cytotoxic aggregates, but also enriches poorly folded aggregates for subsequent removal [54]. Autophagy is a multi-step progression well characterized by the construction of an insulating membrane, named phagophore, which swells to form the double-membrane autophagosome and fuses with the lysosome to degrade the sequestered cytoplasmic cargo [52,55]. Unlike proteasomes, autophagy does not require substrate expansion and is capable of degrading large protein complexes, protein aggregates, and even entire organelles [56,57]. Moreover, autophagy is a precisely controlled process involving multiple proteins encoded by the Atg (autophagy-related) genes [58,59], and previous studies revealed that autophagy is induced in response to oxidative stress or proteasomal damage and is directly involved in the elimination of aggresomes [60,61].

Emerging evidence suggests that autophagy is responsible for the removal of aggregated and misfolded proteins, and the inhibition of autophagy preferentially affects the degradation of mutant proteins associated with neurodegenerative diseases while leaving their wild-type counterparts unaffected [62]. Although the mechanism of autophagy for the specific elimination of misfolded proteins is not yet clear at the molecular level, the selective isolation of incorrectly folded proteins in aggresomes can facilitate the preferential removal of abnormal autophagy proteins [63]. By chelating the endogenous autophagy inhibitor mTOR (mammalian target of rapamycin) kinase [64], the aggresome can also contribute to the initiation of autophagy [65,66]. Importantly, the conventional concept of autophagy only involves the non-selective removal of misfolded proteins and regular cellular proteins, whereas the aggresome–autophagy pathway is specific to aggregated and misfolded proteins. Therefore, a special type of autophagy induction is thought to be related to the specific elimination of toxicity linked to the aggresome formation. One potential mechanism has been found in parkin-mediated, Lys63-linked polyubiquitination which promotes the elimination of misfolded proteins via autophagy, and autophagy occurs by binding to the adapter protein p62 [67], an Ub binding protein interacting with the ubiquitinated proteins via the autophagic mechanical component LC3 through its UBA domain (connected to Ub) and the 22 amino acid LIR (LC3 interaction region) [68]. p62 promotes the binding of a polyubiquitin chain linked to Lys63 [30,31], and the inhibition of its UBA or LIR domain changes the conditions of the ubiquitinated aggregates in the autophagosomes [69,70]. According to recent evidence, p62 may also promote the formation of protein aggregates in addition to promoting the elimination of autophagy [71]. Further studies are required to determine whether p62 is indeed an Ub receptor that regulates the processing of Lys63-linked, folded, polyubiquitinated proteins via an active aggresome–autophagy pathway [72] (Figure 4). As a result, under various stress conditions, an unnecessary level of misfolded proteins is produced in cells as a result of overproduction and UPS damage, resulting in the creation of huge numbers of protein aggregates. p62, a autophagic cargo receptor first identified in mammalian cells, is essential for the development and autophagic removal of intracellular protein aggregates [73]. Biologically, the autophagic elimination of these p62-positive aggregates provides not only the removal of protein aggregates, but
also the maintenance of p62’s homeostatic level [74]. This is significant since intracellular p62 production has been linked to the malignant transformation of autophagy-deficient cells [75]. It was recently proposed that, like some other cytoplasmic membraneless compartments, the arranged p62-positive protein aggregates seem to be actually liquid droplets created by phase separation, which is dependent on the relationship between p62 as well as ubiquitin and can also be regulated by p62 post-translational modification [76]. These cytoplasmic aggregates made up of p62 and poly-Ub proteins are also known as p62 inclusion bodies [77]. Therefore, the creation of p62 bodies increases cell survival under nutritional deprivation conditions, in addition to promoting their own breakdown via selective autophagy.

Figure 4. The regulation of aggresome–autophagy pathway. Aggresome and autophagy are regulated by Lys63-associated polyubiquitination-mediated pathway. Oxidative damage or genetic mutations are responsible for protein misfolding. After folding, the misfolded proteins are labeled with polyubiquitin chains linked to Lys48, which is subsequently degraded via either the proteasomal system or chaperone-mediated pathway. However, when proteasome and chaperone systems are overwhelmed, misfolded proteins form oligomers or aggregates with cellular toxicity. Moreover, PD-related parkin ligase E3 acts with the E2 enzymes Ubc13/Uev1a to facilitate Lys63-associated polyubiquitination of misfolded proteins in proteasome injury conditions. Polyubiquitin chain stimulates binding with HDAC6, and the misfolded proteins bind to dynein motor complex, which retrograde the aggresomes to MTOC via transport. Polyubiquitination encourages p62 binding in addition to recruiting autophagic membranes to form autophagosomes. Consequently, the fusion of autophagosomes and lysosomes facilitates the degradation of misfolded and aggregated proteins through the lysosomal hydrolases.
6. Molecular Mechanism of the Fusion of Aggresome and Lysosome

In the final stage of degradation, fully matured and closed membrane aggresomes fuse with lysosomes to form hybrid compartment organelles called “autolysosomes” which digest their contents [39] (Figure 2). Although the fusion process is morphologically well characterized, its mechanism remains relatively elusive at the molecular level. Typically, the separation membrane is fused with the lysosomal membrane, and then, the lysosomal hydrolase breaks down the content of the fused (or aggresome/lysosome) autolysosome. The substance (amino acid, etc.) is eventually degraded, and is then either recycled or removed into the extracellular space [78]. Subsequently, the lysosomal fraction of the autolysosomes is recovered to produce new lysosomes [79]. Rab7A (Ypt7 in yeast), mature autophagosomes, HOPS (homologous protein fusion and classification complex), and SNARE receptor (SNAP (soluble adhesion protein NSF)) (NSF, fusion-sensitive) labeled (ethyl-maleimide) proteins are essential for the fusion of autophagosomes and lysosomes [78]. The SNAREs increase the permeability of the membrane, indicating that the membranes open and fuse the content of two adjacent organelles [80]. The Rab7A is transformed into an active form linked to GTP through the action of HOPS (Figure 2). The fusion of organelle binding is dependent on the complex of Rab7A and HOPS (Rab7A downstream effector), which is present in two membranes fused, and SNARE and Rab7A are enriched at the fusion site [81]. SNAREs are also required for the expansion and closure of autophagosomal membranes, the early stages of autophagy, and for the transportation of Atg9 (a transmembrane protein necessary for membrane development) [82]. Recently, it has been found that the SNARE protein syntaxin 17 (STX17) is employed in the outer membrane of autophagosomes and mediates lysosomal fusion [83,84]. The depletions of STX17 prevent the destruction of autolysosomes and leads to the accumulation of autophagosomes in the process of basal and starvation-induced autophagy [85]. It is currently unknown whether STX17 is also involved in selective aggrephagy [86]. Furthermore, when an autophagosomal membrane is formed around the materials to be submerged in the endoplasmic reticulum, STX17 interacts with the autophagosome-labeled Atg14L protein at a very early stage [87,88]. These findings together suggest that STX17 plays an important role at both ends of the autophagy decomposition pathway.

7. The Role of Autophagy in Modulating Aggregation in AD

The crucial function of autophagy in preserving neuronal homeostasis is well established in in vivo studies conducted in mice, in which the inhibition of autophagy results in protein deposition and neurodegeneration over time [89]. Decreased autophagy is related to an increase in age-associated neurodegenerative diseases, such as AD [90]. Defective autophagy typically involves the decreased expression of major receptors for autophagy and altered orientation substrate and autophagosome formation. Emphasis has been placed on several aspects, such as the lack of maturation, degradation, and lysosomal alteration [91]. Interestingly, several genes involved in protein homeostasis in neurodegenerative diseases are mutated, such as the lysosome–autophagy system and ubiquitin–proteasome system [92]. In the cases of neurodegenerative diseases, the first marker of altered autophagy is an abnormal quantity of autophagosomes or amphisomes, which can lead to the generation of ROS and other cytotoxic elements. Incidentally, the accumulation of autophagosomes is characterized by an endogenous pool of amyloidogenic Aβ peptides in animal models with AD [93].

The potential function of SQSTM1/p62 in AD progression and other neurodegenerative disorders has been receiving more attention [94]. Compared to the control group, cytoplasmic SQSTM1/p62 protein levels were found to be reduced in the frontal cortex of AD patients [95,96], indicating that SQSTM1/p62 expression is downregulated [96]. Interestingly, oxidative impairment to the promoter of SQSTM1/p62 leads to the reduction in gene transcription, which also appeared in the brain of AD patients [96]. The histopathological analysis of hippocampal and cortical samples from patients with AD showed that the SQSTM1/p62 protein that is contained in inclusion bodies mainly consists
of phosphorylated tau, TRAF6 (tumor necrosis factor receptor associated 6), and ubiquitin, promoting the formation of aggresomes [97]. Moreover, the co-localization of SQSTM1/p62 and Keap-1 insoluble deposits was observed in AD brain extracts [98], and the impairment to the promoter of SQSTM1/p62 as well as co-localization of SQSTM1/p62 with protein aggregation have been observed in other neuropathies, such as Huntington’s disease, tauopathy, and α-synucleinopathies [94,96]. Several studies suggested that SQSTM1/p62 plays a central role in the transport of tau protein to proteasome [97], and that there is a negative connection between the levels of SQSTM1/p62 and p-tau [99], indicating that reduced SQSTM1/p62 function likely causes the accumulation of tau positive aggregates with age. Notably, a SQSTM1/p62-deficient mouse model had a typical AD phenotype, including p-tau neurofibrillary tangles, memory impairment, and synaptic depletion [100]. In addition to protein homeostasis, these last two effects are consistent with the assumption that autophagy is necessary for cell remodeling and neuronal plasticity, and autophagy is a prerequisite for neurogenesis and memory processes [101]. However, it is unknown whether a change in the levels of SQSTM1/p62 is correlated with the elimination of abnormal aggresomes in AD patients. Collectively, current findings suggest that it would be promising to decrease the formation of aggresomes in AD via modulating autophagy.

8. Potential Therapeutic Action of Autophagy to Control Aggresome Formation in AD Pathogenesis

Natural compounds or small molecules have been used to induce the clearance of aggresomes and to restore or enhance cognitive function in patients with AD [4]. For example, liraglutide has been found to activate the insulin degradation enzyme (IDE), increase cognition function and long-term potentiation (LTP), and reduce Aβ plaque deposition and inflammation in APP/PS1 mice via the mTOR-independent and JNK pathway [102,103]. Additionally, rapamycin, a well-known natural macrolide, was found to mitigate Aβ plaques, liberate cerebral amyloid angiopathy, and enhance memory impairment in the AD mice model of PDAPP, hAPP (J20), and P301S through the inhibition of mTOR activity [104,105]. Moreover, a polyphenolic compound known as curcumin, a PI3K/mTOR inhibitor, not only relieved AD pathology by decreasing Aβ but also repaired spatial memory function in APP/PS1 mice through the degradation of autophagic Aβ aggregates [106]. In clinical trials using JNPL3 mice as an AD model, autophagy induced by methylene blue was shown to decrease the aggregation of insoluble tau through the inhibition of mTOR [107]. Another polyphenol, oleuropein aglycone, also promoted autophagy by releasing Ca^{2+} from the reticulum and preventing the activity of mTOR in TgCRND8 mice, and considerably downregulated Aβ plaque [108]. A carbazole-based fluorophore, SLM, bound to Aβ and prevented Aβ aggregation in 3xTg-AD mouse models by alleviating the pathological and behavioral impairments in AD [109]. Additionally, human prolactin-releasing peptide palmitoylated analog, palm11-PrRP31, was shown to protect neuronal cells in APP/PS1 mice models of AD and decrease astrogliosis, microgliosis, and β-amyloid plaque load as well. [110]. The list of representative natural compounds and small molecules that modulate aggresome formation in AD pathogenesis by enhancing autophagy is summarized in Table 1.
Recently, mTOR-independent transcription factor, TFEB, was shown to reduce aggresome formation and activate autophagy, and several compounds are capable of stimulating TFEB-induced lysosomal biogenesis and mTOR-independent autophagy (Figure 5). For example, ouabain has been found to activate TFEB, decrease the aggregation of p-Tau, and increase cognition function in P301L mice [112]. Cinnamic acid and aspirin were found to activate TFEB promoter and promote lysosomal biogenesis, which decreased the formation of Aβ plaque in a 5 × FAD mice model [113,114]. Trehalose, a disaccharide molecule, activates calcineurin and protein phosphatase-3 CB (PP3CB) by promoting the translocation of TFEB into the nucleus via mTOR-independent autophagy [115]. Additionally, it has been found that, in APP/PS1 mice, trehalose treatment promotes the clearance of Aβ plaque independent of the mTOR pathway [115,116]. Hep14, a cardiac glycoside-ingenol, increased TFEB-induced ALP by activating PKC and inhibiting GSK3β, thus decreasing plaque formation in an APP/PS1 AD mice model [117]. Jiang et al. demonstrated that the treatment of temsirolimus successfully improved the autophagic clearance of hyperphosphorylated tau in the brain of P301S transgenic mice and okadaic-acid-incubated SH-SY5Y cells. In addition, temsirolimus administration improved memory impairments and spatial learning function in P301S mice [118]. Small-molecule or natural compounds may control autophagy–lysosomal process via mTOR- and TFEB-mediated pathways, which is summarized in Figure 3.
Figure 5. Mechanism of natural compounds or small molecules to activate mTOR and TFEB in autophagy-lysosomal process. Natural compounds or small molecules inactivate AKT and mTOR, which promote the accumulation of TFEB in the cytoplasmic and its nuclear translocation. TFEB in cytoplasm is heavily phosphorylated and interacts with mTOR in the lysosome surface. The inactivation of mTOR activity stimulates the dephosphorylation of TFEB. Subsequently, dephosphorylated TFEB is translocated from cytoplasm to nucleus. In nucleus, TFEB binds to the promoter regions of autophagy- and lysosomal-associated genes and induces gene expression in addition to lysosome biogenesis. The aggresome is bound to the phagophore, resulting in the formation of the autophagosome. Eventually, the autophagosome fused with lysosome degrades aggresomes via aggrephagy process.

9. Future Prospective of Inhibiting Aggresome Formation as a Treatment for AD

Recently, extensive resources were dedicated to the development of high-performance, automated detection platforms to identify compounds that can prevent aggresome development and endorse aggresome formation [119]. Such high-performance screening primarily uses large libraries designed for general-purpose detection, which serves as a useful approach when running screens with unknown targets or with no structural information available [119,120]. These screenings play an important role in drug discovery
and the creation of new forms of chemical treatment [119,120]. However, since protein aggregation and the formation of aggresomes are complex and mediated by multi-step processes [14], special care must be taken in interpreting the results, especially when aggresome-related genes are used as reporter genes. For example, inhibiting the early stage of the autophagy pathway reduces the formation of aggresomes and the levels of toxic protein species [121] (Figure 6). However, although preventing the late stages of the autophagic pathway reduces aggresome development, it was shown to increase the assembly of soluble, toxic protein species. This complexity highlights the importance of verifying and characterizing the target sites as well as working mechanisms of candidate compounds. The familial form of Alzheimer’s disease (FAD), resulting from mutations in the PRESENILIN 1 (PSEN1) as well as APP genes, accounts for less than 5% of all AD cases and manifests itself early [122]. An iPSC line generated from a FAD patient with the PSEN1-G206D mutation was created and characterized. The iPSC line kept its original genotype as well as karyotype, was free of Sendai viral vectors and reprogramming factors (OCT4, c-MYC, SOX2, and KLF4), had a typical morphology, expressed endogenous pluripotency markers, and could be differentiated into ectodermal, mesodermal, as well as endodermal cells, clarifying its pluripotency [123,124]. PSEN1 mutations cause severe cognitive deterioration, which is largely caused by Aβ oligomerization and accumulation, as well as Tau phosphorylation [125]. The iPSC line revealed here will allow researchers to investigate the involvement of Aβ, p-Tau, and other pathways in FAD, paving the way for new treatments for the condition [126]. Therefore, patient-specific iPSCs include defective genes and may be an ideal cell model for studying the pathophysiology of AD, aiding in the medication screening of AD treatment.

**Figure 6.** Regulation of misfolded protein by autophagy. Misfolded proteins are recognized and polyubiquitinated by ubiquitin E3 protein ligases. Adapter proteins, such as HDAC6, ataxin3, and ubiquitin-1, bind to polyubiquitinated proteins on the dynein motor complex for retrograde transport to the aggressor. Aggresome takes over the autophagy mechanism, including HDAC6, and breaks down aggresome. Several steps along this path enable small molecules to block incorrect protein folding and improve the coupling of folded proteins to dynein for retrograde transport, or improve the clearance of aggresome by autophagy, which can be potentially applied in the treatment of neurodegenerative diseases.
10. Conclusions

Autophagy enhancers that can be utilized for the potential treatment of neurodegenerative diseases are receiving growing attention in recent studies [20,127–129]. It has been shown that the inactivation of mTOR via the lipophilic macrolide antibiotic rapamycin promotes the induction of autophagy [130]. Furthermore, the long-term administration of rapamycin can reduce amyloid loads in mouse models of AD and improve the cognitive function as well as the pathology of tauopathy [131,132]. In addition, post-translational modifications, such as ubiquitination, acetylation, O-GlcNAcylation, and phosphorylation, also appear to exert a positive effect on autophagy [70,133]. Acetylation is an important cellular mechanism that protects cells from stress stimuli and can be changed in neurodegenerative pathologies, highlighting acetylation and deacetylation processes as potential therapeutic candidates for neurodegenerative diseases. Several selective, small-molecule inhibitors of HDAC6 have been identified [134]. For example, tubastatin A promotes the acetylation of α-tubulin, stabilizes the microtubule network, and confers neuroprotection on neurons during in vitro culture and neurodegeneration. By clarifying the mechanism underlying the selection of lysosomal loads, an autophagy-based approach will serve as a more effective therapeutic candidate [135]. In the case of AD, aggresome formation can occur, which can induce the inhibition of proteasome activity. Aggrephagy and its downstream signaling cascades offer promising new therapeutic targets for preventing AD, and further research is required to clarify the relationship between the mechanisms involved in autphagic activities and the formation of aggresomes.

Author Contributions: M.A.R. designed and proposed the original idea for this manuscript. M.H.R. prepared the figures, and A.N.M.M.-O.-R. wrote the draft. H.H. and S.C. reviewed the manuscript. B.K. and H.R. reviewed the scientific contents of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by an intramural funding from Korea Institute of Science and Technology (2E31511). This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1I1A2066868), the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2020R1A5A2019413).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Request upon corresponding author.

Conflicts of Interest: The authors declare that they have no conflict of interest.

References
1. Johnston, J.A.; Ward, C.L.; Kopito, R.R. Aggresomes: A cellular response to misfolded proteins. J. Cell Biol. 1998, 143, 1883–1898. [CrossRef] [PubMed]
2. Takalo, M.; Salminen, A.; Soininen, H.; Hiltnen, M.; Haapasalo, M. Protein aggregation and degradation mechanisms in neurodegenerative diseases. Am. J. Neurodegener. Dis. 2013, 2, 1–14. [PubMed]
3. Hyttinen, J.M.T.; Amadio, M.; Viiri, J.; Pascale, A.; Salminen, A.; Kaarniranta, K. Clearance of misfolded and aggregated proteins by aggrephagy and implications for aggregation diseases. Ageing Res. Rev. 2014, 18, 16–28. [CrossRef] [PubMed]
4. Malampati, S.; Song, J.X.; Tong, B.C.K.; Nalluri, A.; Yang, C.B.; Wang, Z.Y.; Sreenivasamurthy, S.G.; Zhu, Z.; Liu, J.; Su, C.F.; et al. Targeting Aggrephagy for the Treatment of Alzheimer’s Disease. Cells 2020, 9, 311. [CrossRef] [PubMed]
5. Ricciarelli, R.; Fedele, E. The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind. Curr. Neuropharmacol. 2017, 15, 926–935. [CrossRef]
6. Sabbagh, M.N. Alzheimer’s Disease Drug Development Pipeline 2020. J. Prev. Alzheimer’s Dis. 2020, 7, 66–67. [CrossRef]
7. Cleary, J.P.; Walsh, D.M.; Hofmeister, J.J.; Shankar, G.M.; Kuskowski, M.A.; Selkoe, D.J.; Ashe, K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8, 79–84. [CrossRef]
8. Shankar, G.M.; Li, S.; Mehta, T.H.; Garcia-Munoz, A.; Shepardson, N.E.; Smith, J.; Brett, F.M.; Farrell, M.A.; Rowan, M.J.; Lemere, C.A.; et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med. 2008, 14, 837–842. [CrossRef]
9. Guimaraes, R.S.; Delorme-Axford, E.; Klionsky, D.J.; Reggiori, F. Assays for the biochemical and ultrastructural measurement of selective and nonselective types of autophagy in the yeast Saccharomyces cerevisiae. Methods 2015, 75, 141–150. [CrossRef]

10. Kraft, C.; Reggiori, F.; Peter, M. Selective types of autophagy in yeast. Biochim. Biophys. Acta 2009, 1793, 1404–1412. [CrossRef]

11. Rousseau, A.; Bertolotti, A. Regulation of proteasome assembly and activity in health and disease. Nat. Rev. Mol. Cell Biol. 2018, 19, 697–712. [CrossRef] [PubMed]

12. Kroemer, G.; Marino, G.; Levine, B. Autophagy and the integrated stress response. Mol. Cell 2010, 40, 280–293. [CrossRef] [PubMed]

13. Ravikumar, B.; Rubinsztein, D.C. Can autophagy protect against neurodegeneration caused by aggregate-prone proteins? Neuroreport 2004, 15, 2443–2445. [CrossRef]

14. Olzmann, J.A.; Li, L.; Chin, L.S. Aggresome formation and neurodegenerative diseases: Therapeutic implications. Curr. Med. Chem. 2008, 15, 47–60. [PubMed]

15. Gregersen, N. Protein misfolding disorders: Pathogenesis and intervention. J. Inherit. Metab. Dis. 2006, 29, 456–470. [CrossRef] [PubMed]

16. Chin, L.S.; Olzmann, J.A.; Li, L. Parkin-mediated ubiquitin signalling in aggresome formation and autophagy. Biochem. Soc. Trans. 2010, 38, 144–149. [CrossRef]

17. Ravikumar, B.; Duden, R.; Rubinsztein, D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 2002, 11, 1107–1117. [CrossRef]

18. Sorgdrager, F.J.H.; Vermeiren, Y.; Van Faassen, H.J.R.; Van Der Ley, C.P.; Nollen, E.A.A.; Kema, I.P.; De Deyn, P.P. Age- and Disease-Specific Changes of the Kynurenine Pathway in Parkinson’s and Alzheimer’s Disease. J. Neurochem. 2019, 151, 656–668. [CrossRef]

19. Castro-Chavira, S.A.; Fernandez, T.; Perlson, E.; Bronfman, F.C. Neurodegeneration and Alzheimer’s disease (AD). What potential and persisting obstacles. Biochim. Biophys. Acta Neuropathol. 2016, 175, 47–60. [PubMed]

20. Rahman, M.A.; Rhim, H. Therapeutic implication of autophagy in neurodegenerative diseases. BMB Rep. 2017, 50, 345–354. [CrossRef]

21. Moya-Alvarado, G.; Gershoni-Emek, N.; Perlson, E.; Bronfman, F.C. Neurodegeneration and Alzheimer’s disease (AD). What Can Proteomics Tell Us About the Alzheimer’s Brain? Mol. Cell Proteom. 2016, 15, 409–425. [CrossRef] [PubMed]

22. Rahman, M.A.; Rahman, M.S.; Uddin, M.J.; Mamun-Or-Rashid, A.N.M.; Pang, M.G.; Rhim, H. Emerging risk of environmental factors: Insight mechanisms of Alzheimer’s diseases. Environ. Sci. Pollut. R. 2020, 27, 44659–44672. [CrossRef] [PubMed]

23. Rahman, M.A.; Rahman, M.S.; Rahman, M.H.; Rasheduzzaman, M.; Mamun-Or-Rashid, A.N.M.; Uddin, M.J.; Rahman, M.R.; Hwang, H.; Pang, M.G.; Rhim, H. Modulatory Effects of Autophagy on APP Processing as a Potential Treatment Target for Alzheimer’s Disease. Biomedicines 2021, 9, 5. [CrossRef]

24. Sadleir, K.R.; Kandalepas, P.C.; Buggia-Prevot, V.; Nicholson, D.A.; Thinakaran, G.; Vassar, R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Abeta generation in Alzheimer’s disease. Acta Neuropathol. 2016, 132, 235–256. [CrossRef] [PubMed]

25. Abernathy, E.; Mateo, R.; Majzoub, K.; van Buureen, N.; Bird, S.W.; Carette, J.E.; Kirkegaard, K. Differential and convergent utilization of autophagy components by positive-strand RNA viruses. PLoS Biol. 2019, 17, e2006926. [CrossRef] [PubMed]

26. Shabaninia, M.; Turchi, A.; Di Carlo, H.; Gearhart, J.P. Autophagy, apoptosis, and cell proliferation in extrophy-epispadias complex. Urology 2018, 111, 157–161. [CrossRef]

27. Zhang, D.; Gao, C.; Li, R.; Zhang, L.; Tian, J. TEOA, a triterpenoid from Actinidia eriantha, induces autophagy in SW620 cells via endoplasmic reticulum stress and ROS-dependent mitophagy. Arch. Pharmacal Res. 2017, 40, 579–591. [CrossRef]

28. Cordani, M.; Sánchez-Alvarez, M.; Strippoli, R.; Bazzin, A.V.; Donadelli, M. Sestrins at the interface of ROS control and autophagy regulation in health and disease. Oxidative Med. Cell. Longev. 2019, 2019, 1283075. [CrossRef]

29. Galluzzi, L.; Pedro, J.M.B.-S.; Levine, B.; Green, D.R.; Kroemer, G. Pharmacological modulation of autophagy: Therapeutic potential and persisting obstacles. Nat. Rev. Drug Discov. 2017, 16, 487. [CrossRef]

30. Li, M.; Jia, J.; Zhang, X.; Dai, H. Selective binding of mitophagy receptor protein Bcl-rambo to LC3/GABARAP family proteins. Biochem. Biophys. Res. Commun. 2020, 530, 292–300. [CrossRef]

31. Chmurska, A.; Matczak, K.; Marczak, A. Two Faces of Autophagy in the Struggle against Cancer. Int. J. Mol. Sci. 2021, 22, 2981. [CrossRef] [PubMed]

32. Rahman, M.A.; Cho, Y.; Nam, G.; Rhim, H. Antioxidant Compound, Oxyresveratrol, Inhibits APP Production through the AMPK/ULK1/mTOR-Mediated Autophagy Pathway in Mouse Cortical Astrocytes. Antioxidants 2021, 10, 408. [CrossRef] [PubMed]

33. Rahman, M.A.; Hannan, M.A.; Dash, R.; Rahman, M.H.; Islam, R.; Uddin, M.J.; Sohag, A.A.; Rahman, M.H.; Rhim, H. Phytochemicals as a Complement to Cancer Chemotherapy: Pharmacological Modulation of the Autophagy-Apoptosis Pathway. Front. Pharmacol. 2021, 12, 639628. [CrossRef] [PubMed]

34. Li, X.; Sun, L.; Yan, G.; Yan, X. PFKP facilitates ATG4B phosphorylation during amino acid deprivation-induced autophagy. Cell. Signal. 2021, 82, 109956. [CrossRef]

35. Mizushima, N. The ATG conjugation systems in autophagy. Curr. Opin. Cell Biol. 2020, 63, 1–10. [CrossRef]
36. Akter, S.; Rahman, M.A.; Hasan, M.N.; Akhter, H.; Noor, P.; Islam, R.; Shin, Y.; Rahman, M.D.H.; Gazi, M.S.; Huda, M.N.; et al. Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. *Cells* 2022, 11, 650. [CrossRef]

37. Piffieux, M.; Eriau, E.; Cassier, P.A. Autophagy as a therapeutic target in pancreatic cancer. *Br. J. Cancer* 2020, 124, 1–12. [CrossRef]

38. Lamark, T.; Johansen, T. Aggrephagy: Selective disposal of protein aggregates by macroautophagy. *Int. J. Cell Biol.* 2012, 2012, 736905. [CrossRef]

39. Suresh, S.N.; Chakravorty, A.; Giridharan, M.; Garimella, L.; Manjithaya, R. Pharmacological Tools to Modulate Autophagy in Neurodegenerative Diseases. *J. Mol. Bio.* 2020, 432, 2822–2842. [CrossRef]

40. Fortun, J.; Dunn, W.A.L., Jr.; Joy, S.; Li, J.; Notterpek, L. Emerging role for autophagy in the removal of aggresomes in Schwann cells. *J. Neurosci.* 2003, 23, 10672–10680. [CrossRef]

41. Kopito, R.R. Aggresomes, inclusion bodies and protein aggregation. *Trends Cell Biol.* 2000, 10, 524–530. [CrossRef]

42. Markossian, K.A.; Kurganov, B.I. Protein folding, misfolding, and aggregation. Formation of inclusion bodies and aggresomes. *Biochem. Mosc.* 2004, 69, 971–984. [CrossRef]

43. Ventura, S. Sequence determinants of protein aggregation: Tools to increase protein solubility. *Microb. Cell Fact.* 2005, 4, 11. [CrossRef] [PubMed]

44. Ouyang, H.; Ali, Y.O.; Ravichandran, M.; Dong, A.; Qiu, W.; MacKenzie, F.; Dhe-Paganon, S.; Arrowsmith, C.H.; Zhai, R.G. Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini. *J. Biol. Chem.* 2012, 287, 2317–2327. [CrossRef] [PubMed]

45. Li, Y.; Shin, D.; Kwon, S.H. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. *EMBO Rep.* 2019, 20, 343203. [CrossRef] [PubMed]

46. Xu, Z.; Graham, K.; Foote, M.; Liang, F.S.; Rizkallah, R.; Hurt, M.; Wang, Y.C.; Wu, Y.Y.; Zhou, Y. 14-3-3 protein targets misfolded chaperone-associated proteins to aggresomes. *J. Cell Sci.* 2013, 126, 4173–4186. [CrossRef] [PubMed]

47. Heir, R.; Ablasou, C.; Dumontier, E.; Elliott, M.; Fagotto-Kaufmann, C.; Bedford, F.K. The UBL domain of PLIC-1 regulates aggresome formation. *EMBO Rep.* 2006, 7, 1252–1258. [CrossRef]

48. Dikic, I.; Elazar, Z. Mechanism and medical implications of mammalian autophagy. *Nat. Rev. Mol. Cell Biol.* 2018, 19, 349–364. [CrossRef] [PubMed]

49. Chen, R.H.; Chen, Y.H.; Huang, T.Y. Ubiquitin-mediated regulation of autophagy. *J. Biomed. Sci.* 2019, 26, 80. [CrossRef] [PubMed]

50. Li, Y.; Shin, D.; Kwon, S.H. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. *FEBS J.* 2013, 280, 775–793. [CrossRef] [PubMed]

51. Ryhanen, T.; Viiri, J.; Hyttinen, J.M.T.; Uusitalo, H.; Salminen, A.; Kaarniranta, K. Influence of Hsp90 and HDAC Inhibition and Tubulin Acetylation on Perinuclear Protein Aggregation in Human Retinal Pigment Epithelial Cells. *J. Biomed. Biotechnol.* 2011, 2011, 798052. [CrossRef] [PubMed]

52. Rahman, M.A.; Saha, S.K.; Rahman, M.S.; Uddin, M.J.; Uddin, M.S.; Pang, M.G.; Rhim, H.; Cho, S.G. Molecular Insights into Therapeutic Potential of Autophagy Modulation by Natural Products for Cancer Stem Cells. *Front. Cell Dev. Biol.* 2020, 8, 283. [CrossRef] [PubMed]

53. Sanchez, A.D.; Feldman, J.L. Microtubule-organizing centers: From the centrosome to non-centrosomal sites. *Curr. Opin. Cell Biol.* 2017, 44, 93–101. [CrossRef]

54. Sweeney, P.; Park, H.; Baumann, M.; Dunlop, J.; Frydman, J.; Kopito, R.; McCampbell, A.; Leblanc, G.; Venkateswaran, A.; Nurmi, A.; et al. Protein misfolding in neurodegenerative diseases: Implications and strategies. *Transl. Neurodegener.* 2017, 6, 6. [CrossRef] [PubMed]

55. Rahman, M.A.; Rahman, M.R.; Zaman, T.; Uddin, M.S.; Islam, R.; Abdel-Daim, M.M.; Rhim, H. Emerging Potential of Naturally Occurring Autophagy Modulators Against Neurodegeneration. *Curr. Pharm. Des.* 2020, 26, 772–779. [CrossRef]

56. Rahman, M.A.; Hwang, H.; Nah, S.Y.; Rhim, H. Gintonin stimulates autophagic flux in primary cortical astrocytes. *J. Ginseng Res.* 2020, 44, 67–78. [CrossRef]

57. Yim, W.W.Y.; Mizushima, N. Lysosome biology in autophagy. *Cell Discov.* 2020, 6, 6. [CrossRef]

58. Li, X.H.; He, S.K.; Ma, B.Y. Autophagy and autophagy-related proteins in cancer. *Mol. Cancer* 2020, 19, 12. [CrossRef]

59. Rahman, M.A.; Bishayee, K.; Habib, K.; Sadra, A.; Huh, S.O. 18alpha-Glycyrrhetinic acid lethality for neuroblastoma cells via de-regulating the Beclin-1/Bcl-2 complex and inducing apoptosis. *Biochem. Pharmacol.* 2016, 117, 97–112. [CrossRef] [PubMed]

60. Kocaturk, N.M.; Gozuacik, D. Crosstalk Between Mammalian Autophagy and the Ubiquitin-Proteasome System. *Front. Cell Dev. Biol.* 2018, 6, 128. [CrossRef]

61. Uddin, M.S.; Al Abdullah, A.; Rahman, M.A.; Kabir, M.T.; Alkahtani, S.; Alanaizi, I.S.; Perveen, A.; Ashraf, G.M.; Bin-Jumah, M.N.; Abdel-Daim, M.M. Exploring the Promise of Flavonoids to Combat Neuropathic Pain: From Molecular Mechanisms to Therapeutic Implications. *Front. Neurosci.* 2020, 14, 478. [CrossRef] [PubMed]

62. Peker, N.; Gozuacik, D. Autophagy as a Cellular Stress Response Mechanism in the Nervous System. *J. Mol. Biol.* 2020, 432, 2560–2588. [CrossRef] [PubMed]

63. Fredrickson, E.K.; Gardner, R.G. Selective destruction of abnormal proteins by ubiquitin-mediated protein quality control degradation. *Semin. Cell Dev. Biol.* 2012, 23, 530–537. [CrossRef] [PubMed]
92. Nedelsky, N.B.; Todd, P.K.; Taylor, J.P. Autophagy and the ubiquitin-proteasome system: Collaborators in neuroprotection. *Biochim. Biophys. Acta BBA Mol. Basis Dis.* 2008, 1782, 691–699. [CrossRef] [PubMed]

93. Baranello, R.J.; Bharani, K.L.; Padmaraju, V.; Chopra, N.; Lahiri, D.K.; Greig, N.H.; Pappolla, M.A.; Sambamurti, K. Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease. *Curr. Alzheimer Res.* 2015, 12, 32–46. [CrossRef] [PubMed]

94. Martin, P.S.; Komatsu, M. p62/SQSTM1—steering the cell through health and disease. *J. Cell Sci.* 2018, 131, 222836. [CrossRef] [PubMed]

95. Caccamo, A.; Ferreira, E.; Branca, C.; Oddo, S. p62 improves AD-like pathology by increasing autophagy. *Mol. Psychiatry* 2017, 22, 865–873. [CrossRef] [PubMed]

96. Du, Y.F.; Wooten, M.C.; Wooten, M.W. Oxidative damage to the promoter region of SQSTM1/p62 is common to neurodegenerative disease. *Neurobiol. Dis.* 2009, 35, 302–310. [CrossRef]

97. Babu, J.R.; Geetha, T.; Wooten, M.W. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. *J. Neurochem.* 2005, 94, 192–203. [CrossRef]

98. Yang, Y.; Willis, T.L.; Button, R.W.; Strang, C.J.; Fu, Y.H.; Wen, X.; Grayson, P.R.C.; Evans, T.; Sipthorpe, R.J.; Roberts, S.L.; et al. Cytoplasmic DAXX drives SQSTM1/p62 phase condensation to activate Nrf2-mediated stress response. *Nat. Commun.* 2019, 10, 3799. [CrossRef]

99. Ma, S.F.; Attarwala, I.Y.; Xie, X.Q. SQSTM1/p62: A Potential Target for Neurodegenerative Disease. *ACS Chem. Neurosci.* 2019, 10, 2094–2114. [CrossRef]

100. Babu, J.R.; Seibenhener, M.L.; Peng, J.M.; Strom, A.L.; Kemppainen, R.; Cox, N.; Zhu, H.N.; Wooten, M.C.; Diaz-Meco, M.T.; Moscat, J.; et al. Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. *J. Neurochem.* 2008, 106, 107–120. [CrossRef]

101. Glatigny, M.; Moriceau, S.; Rivagorda, M.; Ramos-Brossier, M.; Nascimbeni, A.C.; Lante, F.; Shanley, M.R.; Boudarene, N.; Rousseaud, A.; Friedman, A.K.; et al. Autophagy is Required for Memory Formation and Reverses Age-Related Memory Decline. *Curr. Biol.* 2019, 29, 435–448. [CrossRef]

102. McClean, P.L.; Holscher, C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. *Neuropharmacology* 2014, 76, 57–67. [CrossRef] [PubMed]

103. Kong, J.J.; Wan, L.P.; Wang, Y.F.; Zhang, H.; Zhang, W. Liraglutide Attenuates A beta 42 Generation in APPswe/SH-SY5Y Cells Through the Regulation of Autophagy. *Neuropsych. Dis. Treat.* 2020, 16, 1817–1825. [CrossRef] [PubMed]

104. Lin, A.L.; Zheng, W.; Halloran, J.J.; Burbank, R.R.; Hussong, S.A.; Hart, M.J.; Javors, M.; Shi, Y.Y.I.; Muir, E.; Fonseca, R.S.; et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer’s disease. *J. Cereb. Blood Flow Metab.* 2013, 33, 1412–1421. [CrossRef] [PubMed]

105. Ozcelik, S.; Fraser, G.; Castets, P.; Schaeffer, V.; Skachokova, Z.; Breu, K.; Clavaguera, F.; Sinnreich, M.; Kappos, L.; et al. Fisetin stimulates autophagic process of beta-amyloid pathology in P301S Tau Transgenic Mice. *PLoS ONE* 2013, 8, e62459. [CrossRef]

106. Wang, C.; Zhang, X.P.; Zhang, T.; Li, Y. Downregulation of PI3K/Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 transgenic mice. *Eur. J. Pharmacol.* 2014, 740, 312–320. [CrossRef]

107. Congdon, E.E.; Wu, J.W.; Myeku, N.; Figueroa, Y.H.; Herman, M.; Marinec, P.S.; Gestwicki, J.E.; Dickey, C.A.; Yu, W.H.; Duff, K.E. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. *Autophagy* 2012, 8, 609–622. [CrossRef]

108. Luccarini, I.; Grossi, C.; Rigacci, S.; Coppi, E.; Pugliese, A.M.; Pantano, D.; Ia Marca, G.; Ed Dami, T.; Berti, A.; Stefani, M.; et al. Oleuropein aglycone protects against pyroglutamylated-3 amyloid-ss toxicity: Biochemical, epigenetic and functional correlates. *Neurobiol. Aging* 2015, 36, 648–663. [CrossRef]

109. Wu, X.L.; Kosaraju, J.; Zhou, W.; Tam, K.Y. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer’s Disease. *ACS Chem. Neurosci.* 2017, 8, 676–685. [CrossRef]

110. Holubova, M.; Hruba, L.; Popelova, A.; Bencze, M.; Praženková, V.; Gengl, S.; Kralotichvila, H.; Haluzík, M.; Zelezná, B.; Kunes, J.; et al. Liraglutide and a lipized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of beta-amyloid pathology. *Neuropharmacology* 2019, 144, 377–387. [CrossRef]

111. Kim, S.; Choi, K.J.; Cho, S.J.; Yun, S.M.; Jeon, J.P.; Koh, Y.H.; Song, J.; Johnson, G.V.W.; Jo, C. Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factors. *Sci. Rep.* 2016, 6, 1–13. [CrossRef]

112. Song, H.L.; Demirev, A.V.; Kim, N.Y.; Kim, D.H.; Yoon, S.Y. Ouabain activates transcription factor EB and exerts neuroprotection in models of Alzheimer’s disease. *Mol. Cell Neurosci.* 2019, 95, 13–24. [CrossRef] [PubMed]

113. Chandra, S.; Jana, M.; Pahan, K. Aspirin Induces Lysosomal Biogenesis and Attenuates Amyloid Plaque Pathology in a Mouse Model of Alzheimer’s Disease via PPAR alpha. *J. Neurosci.* 2018, 38, 6682–6699. [CrossRef] [PubMed]

114. Chandra, S.; Roy, A.; Jana, M.; Pahan, K. Cinnamic acid activates PPARalpha to stimulate Lysosomal biogenesis and lower Amyloid plaque pathology in an Alzheimer’s disease mouse model. *Neurobiol. Dis.* 2019, 124, 379–395. [CrossRef] [PubMed]

115. Kruger, U.; Wang, Y.P.; Kumar, S.; Mandellkow, E.M. Autophagic degradation of tau in primary neurons and its enhancement by trehalose. *Neurobiol. Aging* 2012, 33, 2291–2305. [CrossRef] [PubMed]
116. Portbury, S.D.; Hare, D.J.; Sgambelloni, C.; Perronnes, K.; Portbury, A.J.; Finkelstein, D.I.; Adlard, P.A. Trehalose Improves Cognition in the Transgenic Tg2576 Mouse Model of Alzheimer’s Disease. *J. Alzheimers Dis.* 2017, 60, 549–560. [CrossRef] [PubMed]

117. Li, Y.; Xu, M.; Ding, X.; Yan, C.; Song, Z.Q.; Chen, L.W.; Huang, X.H.; Wang, X.; Jian, Y.L.; Tang, G.H.; et al. Protein kinase C controls lysosome biogenesis independently of mTORC1. *Nat. Cell Biol.* 2016, 18, 1065–1077. [CrossRef] [PubMed]

118. Jiang, T.; Yu, J.T.; Zhu, X.C.; Zhang, Q.Q.; Cao, L.; Wang, H.F.; Tan, M.S.; Gao, Q.; Qin, H.; Zhang, Y.D.; et al. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. *Neuropharmacology* 2014, 85, 121–130. [CrossRef]

119. Lesire, L.; Chaput, L.; De Casas, P.C.; Rousseau, F.; Pivotteau, C.; Dumont, J.; Pointu, D.; Deprez, B.; Leroux, F. High-Throughput Image-Based Aggresome Quantification. *SLAS Discov.* 2020, 25, 783–791. [CrossRef]

120. Schmidt, J.; Marques, M.R.G.; Botti, S.; Marques, M.A.L. Recent advances and applications of machine learning in solid-state materials science. *NPJ Comput. Mater.* 2019, 5, 83. [CrossRef]

121. Taylor, J.P.; Tanaka, F.; Robitscheck, J.; Sandoval, C.M.; Taye, A.; Markovic-Plese, S.; Fischbeck, K.H. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. *Hum. Mol. Genet.* 2003, 12, 749–757. [CrossRef]

122. Wang, Z.; Zhang, P.; Wang, Y.; Shi, C.; Jing, N.; Sun, H.; Yang, J.; Liu, Y.; Wen, X.; Zhang, J. Establishment of induced pluripotent stem cell line (ZZU010-A) from an Alzheimer’s disease patient carrying an APP gene mutation. *Stem Cell Res.* 2017, 25, 213–216. [CrossRef] [PubMed]

123. Li, J.; Song, W.; Pan, G.; Zhou, J. Advances in understanding the cell types and approaches used for generating induced pluripotent stem cells. *J. Hematol. Oncol.* 2014, 7, 1–18. [CrossRef] [PubMed]

124. Diaz-Guerra, E.; Oria-Muriel, M.A.; Moreno-Jiménez, E.P.; de Rojas, I.; Rodríguez, C.; Rodríguez-Traver, E.; Orera, M.; Hernández, L.; Ruizb, A.; Vicario, C. Generation of an integration-free iPSC line, ICSCi006-A, derived from a male Alzheimer’s disease patient carrying the PSEN1-G206D mutation. *Stem Cell Res.* 2019, 40, 101574. [CrossRef] [PubMed]

125. Twohig, D.; Nielsen, H.M. α-synuclein in the pathophysiology of Alzheimer’s disease. *Mol. Neurodegener.* 2019, 14, 1–19. [CrossRef] [PubMed]

126. Ranjan, V.; Qiu, L.; Tanaka, F.; Robitscheck, J.; Sandoval, C.M.; Taye, A.; Markovic-Plese, S.; Fischbeck, K.H. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. *Hum. Mol. Genet.* 2003, 12, 749–757. [CrossRef]

127. Guo, F.; Liu, X.; Cai, H.; Le, W. Autophagy in neurodegenerative diseases: Pathogenesis and therapy. *Brain Pathol.* 2018, 28, 3–13. [CrossRef] [PubMed]

128. Uddin, M.S.; Mamun, A.A.; Jakaria, M.; Thangapandiyan, S.; Ahmad, J.; Rahman, M.A.; Mathew, B.; Abdel-Daim, M.M.; Aleya, L. Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders. *Sci. Total Environ.* 2020, 707, 135624. [CrossRef] [PubMed]

129. Uddin, M.S.; Al Mamun, A.; Rahman, M.A.; Behl, T.; Perveen, A.; Hafeez, A.; Bin-Jumah, M.N.; Abdel-Daim, M.M.; Ashraf, G.M. Emerging Proof of Protein Misfolding and Interaction in Multifactorial Alzheimer’s Disease. *Curr. Top. Med. Chem.* 2020, 20, 2380–2390. [CrossRef]

130. Ding, L.; Nan, W.H.; Zhu, X.B.; Li, X.M.; Zhou, L.Y.; Chen, H.J.; Yu, L.; Khan, F.U.; Zhong, H.B.; Shi, X.J. Rapamycin and FK506 derivative TH2849 could ameliorate neurodegenerative diseases through autophagy with low immunosuppressive effect. *CNS Neurosci. Ther.* 2019, 25, 452–464. [CrossRef]

131. Liu, J.; Li, L. Targeting Autophagy for the Treatment of Alzheimer’s Disease: Challenges and Opportunities. *Front. Mol. Neurosci.* 2019, 12, 203. [CrossRef]

132. Cai, Z.; Zhao, B.; Li, K.S.; Zhang, L.Q.; Li, C.H.; Quazi, S.H.; Tan, Y. Mammalian target of rapamycin: A valid therapeutic target through the autophagy pathway for Alzheimer’s disease? *J. Neurosci. Res.* 2012, 90, 1105–1118. [CrossRef] [PubMed]

133. Xie, Y.C.; Kang, R.; Sun, X.F.; Zhong, M.Z.; Huang, J.; Klionsky, D.J.; Tang, D.L. Posttranslational modification of autophagy-related proteins in macroautophagy. *Autophagy* 2015, 11, 28–45. [CrossRef] [PubMed]

134. Cosenza, M.; Pozzi, S. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease. *Int. J. Mol. Sci.* 2018, 19, 2337. [CrossRef] [PubMed]

135. Rubinsztein, D.C.; Codogno, P.; Levine, B. Autophagy modulation as a potential therapeutic target for diverse diseases. *Nat. Rev. Drug Discov.* 2012, 11, 709–784. [CrossRef]